This trial is using a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of CAR.B7-H3 T cell product. An expansion cohort will enroll additional subjects at the RP2D for a total enrollment of up to 21 subjects on the protocol.
1 Primary · 3 Secondary · Reporting Duration: From the date of lymphodepletion to the date of death up to 5 years
21 Total Participants · 1 Treatment Group
Primary Treatment: CAR.B7-H3 · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: